Gene mapping could open new doors for brain tumor patients
NCT ID NCT05186064
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether whole genome sequencing of recurrent glioblastoma tumors can uncover more targeted treatment options. Researchers analyzed tumor samples from 164 patients who had surgery for their first recurrence. The goal was to see if this detailed genetic testing could identify additional therapies beyond standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- whole genome sequencing (diagnostic test)
- What this could lead to
- If successful, this approach could help doctors identify more personalized treatment options for recurrent glioblastoma patients.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly improve survival or outcomes for participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Haaglanden Medisch Centrum
The Hague, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?